Eli Lilly (LLY) said Friday that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for Jaypirca to treat certain adult patients with relapsed or refractory chronic lymphocytic leukemia.
The recommendation is based on data from a phase 3 trial, in which the therapy met its primary endpoint of progression-free survival, Lilly said.
The European Commission will make a final decision in next one or two months, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。